Zhang Huang-Ge, Xie Jinfu, Dmitriev Igor, Kashentseva Elena, Curiel David T, Hsu Hui-Chen, Mountz John D
Division of Clinical Immunology and Rheumatology, Department of Medicine, The University of Alabama at Birmingham, Birmingham, Alabama 35294, USA.
J Virol. 2002 Dec;76(23):12023-31. doi: 10.1128/jvi.76.23.12023-12031.2002.
Production of large quantities of recombinant adeno-associated virus (AAV) is difficult and not cost-effective. To overcome this problem, we have explored the feasibility of creating a recombinant AAV encoding a 6xHis tag on the VP3 capsid protein. We generated a plasmid vector containing a six-His (6xHis)-tagged AAV VP3. A second plasmid vector was generated that contained the full-length AAV capsid capable of producing VP1 and VP2, but not VP3 due to a mutation at position 2809 that encodes the start codon for VP3. These plasmids, necessary for production of AAV, were transfected into 293 cells to generate a 6xHis-tagged VP3mutant recombinant AAV. The 6xHis-tagged VP3 did not affect the formation of AAV virus, and the physical properties of the 6xHis-modified AAV were equivalent to those of wild-type particles. The 6xHis-tagged AAV did not affect the production titer of recombinant AAV and could be used to purify the recombinant AAV using an Ni-nitrilotriacetic acid column. Addition of the 6xHis tag did not alter the viral tropism compared to wild-type AAV. These observations demonstrate the feasibility of producing high-titer AAV containing a 6xHis-tagged AAV VP3 capsid protein and to utilize the 6xHis-tagged VP3 capsid to achieve high-affinity purification of this recombinant AAV.
大量生产重组腺相关病毒(AAV)既困难又不具成本效益。为克服这一问题,我们探索了构建在VP3衣壳蛋白上编码6xHis标签的重组AAV的可行性。我们构建了一个包含六组氨酸(6xHis)标签的AAV VP3的质粒载体。还构建了第二个质粒载体,其包含能够产生VP1和VP2的全长AAV衣壳,但由于在编码VP3起始密码子的第2809位发生突变而不能产生VP3。这些生产AAV所需的质粒被转染到293细胞中以产生带有6xHis标签的VP3突变重组AAV。带有6xHis标签的VP3不影响AAV病毒的形成,并且6xHis修饰的AAV的物理性质与野生型颗粒相当。带有6xHis标签的AAV不影响重组AAV的生产滴度,并且可用于使用镍-次氮基三乙酸柱纯化重组AAV。与野生型AAV相比,添加6xHis标签不会改变病毒嗜性。这些观察结果证明了生产含有带有6xHis标签的AAV VP3衣壳蛋白的高滴度AAV以及利用带有6xHis标签的VP3衣壳实现这种重组AAV的高亲和力纯化的可行性。